Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Transgenic Group's Total Assets for the quarter that ended in Mar. 2026 was 円9,735 Mil.
Warning Sign:
If a company builds assets at 5.5% a year, faster than its revenue growth rate of 4.2% over the past 5 years, it means that the company may be getting less efficient.
During the past 12 months, Transgenic Group's average Total Assets Growth Rate was 8.10% per year.
During the past 3 years, the average Total Assets Growth Rate was 1.80% per year.
During the past 5 years, the average Total Assets Growth Rate was 5.50% per year.
During the past 10 years, the average Total Assets Growth Rate was 10.40% per year.
During the past 13 years, Transgenic Group's highest 3-Year average Total Assets Growth Rate was 52.40%. The lowest was -8.50%. And the median was 10.80%.
Note:
The Net Income data used here is two times the semi-annual (Mar. 2026) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Transgenic Group's Asset Turnover for the quarter that ended in Mar. 2026 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Transgenic Group Total Assets Related Terms
Transgenic Group Total Assets Historical Data
* Premium members only.
The historical data trend for Transgenic Group's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Transgenic Group's Total Assets for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Transgenic Group (TSE:2342) has a Total Assets of 円9,735 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Transgenic Group and its competitors.
Is Transgenic Group's Total Assets too high?
Transgenic Group's current Total Assets is 円9,735 Mil. Overall, Transgenic Group has a GF Score™ of 60/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Transgenic Group's Total Assets compare to VRTX and REGN?
Transgenic Group's Total Assets of 円9,735 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Transgenic Group and its competitors. Transgenic Group's current Total Assets is 円9,735 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Transgenic Group stock overvalued right now?
Based on GuruFocus' analysis, Transgenic Group (TSE:2342) is currently considered Modestly Undervalued. The stock's GF Value™ is 円257.97, compared to a current price of 円212.00 — trading 17.8% below its estimated fair value. The current Total Assets is 円9,735 Mil. Transgenic Group's overall GF Score™ is 60/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Transgenic Group (TSE:2342), the current Total Assets is 円9,735 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Transgenic Group (TSE:2342) Overvalued in 2026?
Based on GuruFocus' analysis, Transgenic Group stock appears to be undervalued.
The current stock price of 円212.00 is trading 17.8% below its estimated GF Value™ of 円257.97.
GuruFocus considers Transgenic Group to be Modestly Undervalued.
Key valuation signals for TSE:2342:
Total Assets: 円9,735 Mil
GF Value™: 円257.97 vs. price of 円212.00 (17.8% below fair value)
No single metric tells the full story. See the TSE:2342 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Transgenic Group Inc formerly Trans Genic Inc is engaged in offering assistance of non-clinical experiments using large animals and general rearing management work, and non-clinical trial service using large animals. The company has two segments: Drug discovery support business, and Investment and consulting business.
60GF Score
Get the complete analysis for TSE:2342
Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:2342 has been successfully added to your 
